Activist DOMA Demands CEO Removal, Company Sale Amidst Proxy Battle
PCRX sits 21% above its 52-week low of $18.8.
Summary
Activist investor DOMA Perpetual Capital Management has intensified its proxy battle against Pacira BioSciences, presenting a detailed case to ISS that accuses management and the board of gross negligence, value destruction, and poor governance, while proposing the removal of the CEO and a sale of the company.
Key Events · Corporate Governance and Compliance · PCRX
-
Activist Intensifies Proxy Battle
Activist investor DOMA Perpetual Capital Management filed additional proxy materials, including a presentation to Institutional Shareholder Services (ISS), detailing its criticisms of Pacira's management and board.
-
Demands CEO Removal and Company Sale
DOMA proposes removing the current CEO, appointing an interim CEO, and forming a board subcommittee to oversee a sale process for the company, with shareholder approval on the final sale price.
-
Alleges Gross Negligence in IP Litigation
DOMA accuses the board of 'gross negligence' for continuing high-stakes patent litigation on EXPAREL (80% of revenue) after a previous loss cost 38% of future volumes, arguing it risks total value destruction.
-
Criticizes Spending and Governance
The activist highlights wasteful spending, including a 44% increase in R&D and 25% in SG&A in 2025, high executive compensation amidst net losses, and a governance structure designed to limit shareholder influence.
Analysis · PCRX · Life Sciences
This filing marks a significant escalation in the ongoing proxy contest, as activist investor DOMA Perpetual Capital Management presented a detailed case to Institutional Shareholder Services (ISS). DOMA's presentation accuses Pacira's management and board of gross negligence, value destruction, and poor governance, particularly regarding high-stakes IP litigation for its core product EXPAREL. The activist's proposal to remove the CEO and initiate a sale process for the entire company represents a fundamental challenge to Pacira's current strategic direction and could lead to a major corporate transaction, making this a highly market-moving event.
At the time of this filing, PCRX was trading at $22.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $898.4M. The 52-week trading range was $18.80 to $27.64. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.